P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer

Rambam Health Care Campus

Status: Completed

Conditions: Serous Papillary Endometrial Cancer

Treatments: Other: no intervention

Study type: Observational

Funder types: Other

Identifiers

NCT01267357

230CTIL

Details and patient eligibility

About

P16 is a tumor suppressor protein implicated in serous papillary endometrial carcinoma. Evidence from previous trials indicates that it may be used as a diagnostic biomarker distinguishing this disease from endometrioid endometrial cancer. Additional evidence points to its prognostic value.

The current study will evaluate p16 both as a diagnostic tool for serous papillary endometrial cancer and as a prognostic biomarker.

following anonymization, histology blocks will be microtomed and stained for P16 and P53 proteins.

Blocks from endometrioid endometrial cancer will be used as a control group.

Enrollment: 62 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosis of endometrial cancer
• histology block exists in hospital's library

Exclusion criteria

• none

Trial design

62 participants in 2 patient groups

Serous papillary endometrial ca patients

Description:

30 patients diagnosed with SP endometrial ca

Treatment:

Other: no intervention

Endometrioid endometrial ca

Description:

32 patients diagnosed with Endometrioid endometrial ca

Treatment:

Other: no intervention